Pasireotide

Pasireotide is a synthetic cyclohexapeptide somatostatin receptor ligand (SRL) with a broader receptor-binding profile than first-generation analogs such as octreotide and lanreotide. Five human somatostatin receptor subtypes (SSTR1 through SSTR5) are known to mediate the diverse physiological effects of endogenous somatostatin. First-generation SRLs bind predominantly to SSTR2 and, to a lesser extent, SSTR5. Pasireotide binds with high affinity to SSTR1, SSTR2, SSTR3, and SSTR5; it does not substantially bind SSTR4. Its affinity for SSTR5 is approximately 158-fold greater than that of octreotide, while its affinity for SSTR2 is approximately 7-fold lower than octreotide.

In Cushing's disease, corticotroph adenoma cells frequently over-express SSTR5. Pasireotide binds to SSTR5 on these cells and inhibits the secretion of adrenocorticotropic hormone (ACTH) from the pituitary, which in turn reduces cortisol production by the adrenal cortex. This direct action on the corticotroph tumor distinguishes pasireotide from adrenal-targeted steroidogenesis inhibitors.

In acromegaly, excess growth hormone (GH) from a pituitary somatotroph adenoma drives elevated insulin-like growth factor 1 (IGF-1) levels and their associated comorbidities. Pasireotide suppresses GH secretion via combined binding to SSTR2 and SSTR5, both expressed on somatotroph cells. The engagement of SSTR5 in addition to SSTR2 may account for the incremental biochemical control observed in patients who are inadequately controlled on SSTR2-preferring analogs.

• The most clinically significant mechanism-related adverse effect is impaired glucose regulation. SSTR5 is highly expressed on pancreatic beta cells; its activation by pasireotide potently inhibits insulin secretion. Unlike SSTR2 activation (which suppresses glucagon via alpha cells), SSTR5 binding does not substantially suppress glucagon, resulting in a net hyperglycemic state that is not fully compensated. Pasireotide also reduces GLP-1 and GIP incretin secretion, compounding the deficit in insulin release.

The pivotal Phase 3 trial for Signifor SC in Cushing's disease (study B2305, published in the New England Journal of Medicine in 2012) enrolled 162 adults with confirmed Cushing's disease, randomizing them to pasireotide 600 mcg or 900 mcg subcutaneously twice daily. The primary endpoint was normalization of mean urinary free cortisol (mUFC) without dose escalation at 6 months. Normalization was achieved by 14.6% in the 600 mcg group and 26.3% in the 900 mcg group. At 12 months, responder rates were 13.4% and 25%, respectively. Median UFC fell by approximately 50% within the first two months and remained stable. Cortisol-dependent clinical features including blood pressure, body weight, and waist circumference improved in responders. Hyperglycemia was the leading adverse event, occurring in approximately 73% of patients.

For Signifor LAR in Cushing's disease, a Phase 3 study (N=150) compared 10 mg and 30 mg IM monthly. At Month 7, mUFC responder rates (UFC at or below the upper limit of normal) were 39.2% and 40.8%, respectively. Rates at Month 12 were 35.1% (10 mg) and 25.0% (30 mg). Median tumor volume reductions of 16–18% were observed.

In acromegaly, the pivotal CS2305 Phase 3 trial enrolled 358 medically naive patients, randomizing them to pasireotide LAR 40 mg or octreotide LAR 20 mg monthly for 12 months. The primary composite endpoint — GH below 2.5 mcg/L and normalized IGF-1 at Month 12 — was achieved by 31.3% on pasireotide LAR versus 19.2% on octreotide LAR (p=0.007). IGF-1 normalization alone was 38.6% versus 23.6% (p=0.002). Median tumor volume reduction was 39.8% at Month 12 with pasireotide, and 98% of patients showed reduction or no change in tumor volume.

The PAOLA Phase 3 trial (Lancet Diabetes and Endocrinology, 2014) enrolled acromegaly patients inadequately controlled on first-generation SRLs and compared pasireotide LAR 40 mg (n=65) or 60 mg (n=65) to continued octreotide or lanreotide (n=68) for 6 months. Biochemical control was achieved by 15.4% and 20.0% in the respective pasireotide arms, versus 0% in the active control arm. Hyperglycemia-related adverse events affected 40–67% of patients across acromegaly LAR trials.

Typical dosage: 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).

Two distinct formulations of pasireotide are used in clinical practice, each with separate dosing recommendations.

Signifor (pasireotide diaspartate, subcutaneous injection) for Cushing's disease: The recommended starting dose is 0.6 mg or 0.9 mg administered by subcutaneous injection twice daily. The dose may be decreased to 0.3 mg twice daily to manage tolerability. The maximum approved dose is 0.9 mg twice daily. The injection is self-administered by the patient after appropriate training.

Signifor LAR (pasireotide, long-acting release) for acromegaly: The recommended initial dose is 40 mg administered by deep intramuscular injection into the gluteal muscle once every 4 weeks. After 3 months, the dose may be increased to a maximum of 60 mg every 4 weeks if GH and/or IGF-1 remain above target, or decreased to 20 mg for tolerability. Signifor LAR must be reconstituted and administered by a trained healthcare professional.

Signifor LAR for Cushing's disease: The recommended initial dose is 10 mg intramuscularly every 4 weeks. After 4 months, escalation up to 40 mg is permitted if mUFC remains above the upper limit of normal. Dose may be reduced for tolerability.

Hepatic impairment (Child-Pugh B): Reduce initial acromegaly LAR dose to 20 mg (maximum 40 mg); Cushing's LAR dose remains 10 mg (maximum 20 mg). Signifor LAR is contraindicated in severe hepatic impairment (Child-Pugh C).

Pre-treatment evaluation includes fasting plasma glucose, HbA1c, ECG, and serum potassium, magnesium, and liver enzymes. Weekly fasting glucose monitoring for the first 3 months of therapy is recommended per the prescribing information, with periodic monitoring thereafter.

This content is provided for educational reference only and does not constitute medical advice. Pasireotide is a prescription medication with significant safety monitoring requirements; all prescribing and dosing decisions must be made by a qualified healthcare professional using the full official prescribing information and individualized clinical assessment.

In Cushing's disease, a stepwise escalation combining pasireotide with cabergoline and ketoconazole has been evaluated clinically. Feelders and colleagues studied 17 patients treated initially with pasireotide monotherapy; if UFC remained elevated after 28 days, cabergoline (0.5–1.5 mg every other day) was added; if needed at 60 days, ketoconazole (200 mg three times daily, totaling 600 mg/day) was added. Pasireotide alone normalized UFC in 5 of 17 patients (29%); adding cabergoline raised the proportion to 9 of 17 (53%); subsequent addition of ketoconazole achieved biochemical control in 15 of 17 patients (88%). The rationale is complementary mechanism engagement: SSTR5 inhibition of ACTH (pasireotide), D2 receptor suppression of the corticotroph (cabergoline), and adrenal 11-beta-hydroxylase blockade (ketoconazole). An important safety caveat applies: both pasireotide and ketoconazole prolong the QTc interval, and their combination requires cardiac monitoring in patients at arrhythmic risk.

In acromegaly, combination of pasireotide LAR with pegvisomant (a GH receptor antagonist) has been described in case series for patients with incomplete IGF-1 normalization on either agent alone. The mechanistic rationale is complementary action: pasireotide reduces GH secretion at the pituitary level, while pegvisomant blocks GH receptor signaling in peripheral tissues. This combination is not FDA-approved as a fixed regimen and is used off-label.

Co-administration of GLP-1 receptor agonists (e.g., liraglutide) or DPP-4 inhibitors with pasireotide is supported by expert consensus specifically for management of pasireotide-induced hyperglycemia rather than for antitumor effect; these agents partially counteract the SSTR5-mediated insulin secretory deficit and are considered the preferred antidiabetic class in this setting.

Pasireotide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism)

Hyperglycemia and diabetes mellitus are the dominant and most clinically significant adverse effects of pasireotide, arising from its potent SSTR5-mediated suppression of pancreatic insulin secretion. Hyperglycemia-related adverse events were reported in approximately 47% of Cushing's disease patients receiving Signifor LAR, 68–73% receiving Signifor SC, and 40–57% of acromegaly patients on Signifor LAR in Phase 3 trials. New-onset or worsening diabetes mellitus requiring antidiabetic therapy developed in approximately 26–27% of patients. Glucose elevations typically peak within the first month and then stabilize. Expert consensus recommends DPP-4 inhibitors or GLP-1 receptor agonists as first-line antidiabetic therapy in this setting; liraglutide co-administration reduced glucose levels by approximately 72% relative to pasireotide alone in a controlled study of healthy volunteers. Metformin monotherapy has insufficient mechanistic efficacy given the insulin secretory defect. Hyperglycemia is reversible upon discontinuation, with return toward baseline within approximately three months.

QT interval prolongation has been observed at therapeutic concentrations, with mean QTc increases of 12.7–16.6 ms documented in electrophysiology studies. Baseline and periodic ECG monitoring is required. Caution is indicated in patients with pre-existing cardiac conduction abnormalities, electrolyte abnormalities (hypokalemia, hypomagnesemia), or co-administration of other QT-prolonging agents. Sinus bradycardia was reported in approximately 10% of acromegaly patients in the LAR trial.

Gastrointestinal adverse events are common: diarrhea (39–58%), nausea (21–52%), and abdominal pain (23–24%). Severity is generally mild to moderate; GI events are more frequent with the subcutaneous than the long-acting formulation.

Cholelithiasis occurred in 26–33% of patients across Phase 3 trials, consistent with the class effect of reduced gallbladder motility. Most cases were asymptomatic. Periodic gallbladder ultrasound monitoring is recommended. Asymptomatic lipase elevations were noted in approximately 30% of drug-naive acromegaly patients; rare pancreatitis cases have been reported.

Liver enzyme elevations greater than three times the upper limit of normal occurred in approximately 4% of acromegaly patients and 14% of Cushing's disease patients. Baseline and periodic liver function monitoring is required; severe hepatic impairment (Child-Pugh C) is a contraindication.

In Cushing's disease, effective cortisol suppression can precipitate hypocortisolism; adrenal function should be assessed and dose temporarily reduced if adrenal insufficiency symptoms emerge.

There is no black box warning on the current prescribing label for either formulation.